Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?

Henry SP; Geary RS; Yu R; Levin AA

Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?

Author(s): Henry SP, Geary RS, Yu R, Levin AA

Abstract

Antisense technology has progressed beyond the point of using only phosphorothioate oligodeoxynucleotides as therapeutic agents to looking at antisense molecules that contain additional chemical modifications as the next generation of therapeutic agents. These modifications are intended to improve the overall therapeutic properties by increasing potency, optimizing pharmacokinetic properties and improving the safety profile. This review will focus on the non-clinical pharmacokinetic and safety properties of 2'-O-methoxyethyl-modified oligonucleotides. Implications on the convenience and safe use of these compounds as therapeutic agents will be discussed.

Referred From: https://www.ncbi.nlm.nih.gov/pubmed/11890363

Journal of Cytokine Biology
has published an article entitled(Chemical Modification of CRISPR gRNAs* Eliminate type I Interferon Responses in Human Peripheral Blood Mononuclear Cells*) & referenced following source

Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?

Abstract

Similar Articles

Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis

The Interferon (IFN) Class of Cytokines and the IFN Regulatory Factor (IRF) Transcription Factor Family

Role of Type I and II Interferons in Colorectal Cancer and Melanoma

Immune responses to gene therapy vectors: influence on vector function and effector mechanisms

Innate immune response induced by gene delivery vectors

Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response

A direct comparison of anti-microRNA oligonucleotide potency

Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys

Chemical Modification of siRNAs for in vivo Use

Simplified CRISPR tools for efficient genome editing and streamlined protocols for their delivery into mammalian cells and mouse zygotes

Detection and quantitative evaluation of endotoxin contamination in nanoparticle formulations by LAL-based assays

Considerations and Some Practical Solutions to Overcome Nanoparticle Interference with LAL Assays and to Avoid Endotoxin Contamination in Nanoformulations

Analysis of Pro-inflammatory Cytokine and Type II Interferon Induction by Nanoparticles

More than 70 years of pyrogen detection: Current state and future perspectives

A human in vitro whole blood assay to predict the systemic cytokine response to therapeutic oligonucleotides including siRNA

Assessment of pyrogenic contaminations with validated human whole-blood assay

Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy

Evidence for the detection of non-endotoxin pyrogens by the whole blood monocyte activation test

International validation of novel pyrogen tests based on human monocytoid cells

Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm

Nucleic acids as therapeutic agents

Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development

Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents

Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development

Aptamers as therapeutics

5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I

Recommended Journals

Related Subjects

Open Access Journals